Viridian Therapeutics, Inc.\DE (VRDN) EPS (Basic) (2013 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly EPS (Basic) came in at -$3.42 in Q1 2026, down 23.18% year-on-year from -$4.45 in Q1 2025, and down 3.04% quarter-over-quarter from -$3.32 in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) EPS (Basic) (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's EPS (Basic) history runs 14 years deep, the most recent figure standing at -$3.42 for Q1 2026.
- On a quarterly basis, EPS (Basic) fell 23.18% year-over-year to -$3.42 in Q1 2026; TTM through Mar 2026 was -$10.93, a 9.86% decrease from a year earlier, with the FY2025 full-year figure at -$21.86, down 40.46% from the prior year.
- EPS (Basic) declined to -$3.42 in Q1 2026 per VRDN's latest filing, from -$3.32 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.86 in Q3 2022 and bottomed at -$3.42 in Q1 2026.
- The 5-year median for EPS (Basic) is -$1.38 (2024), against an average of -$1.77.
- Across the five-year window, EPS (Basic) jumped 66.24% in 2022 and plunged 193.72% in 2025, its largest moves.
- Year by year, EPS (Basic) stood at -$1.42 in 2022, then plunged by 32.37% to -$1.88 in 2023, then tumbled by 37.51% to -$2.59 in 2024, then fell by 28.19% to -$3.32 in 2025, then slipped by 3.04% to -$3.42 in 2026.
- Per Business Quant, the three latest VRDN EPS (Basic) figures stand at -$3.42 (Q1 2026), -$3.32 (Q4 2025), and -$1.02 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | Viridian Therapeutics, Inc.\DE | 631.55 Mn | 631.55 Mn | - | -3.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.42 |
| Dec 31, 2025 | -3.32 |
| Sep 30, 2025 | -1.02 |
| Jun 30, 2025 | -3.31 |
| Mar 31, 2025 | -2.77 |
| Dec 31, 2024 | -2.59 |
| Sep 30, 2024 | -1.38 |
| Jun 30, 2024 | -1.14 |
| Mar 31, 2024 | -0.94 |
| Dec 31, 2023 | -1.88 |
| Sep 30, 2023 | -1.09 |
| Jun 30, 2023 | -1.27 |
| Mar 31, 2023 | -1.61 |
| Dec 31, 2022 | -1.42 |
| Sep 30, 2022 | -0.86 |
| Jun 30, 2022 | -1.06 |
| Mar 31, 2022 | -0.98 |
| Dec 31, 2021 | -2.43 |
| Sep 30, 2021 | -1.26 |
| Jun 30, 2021 | -2.22 |